Women with FIGO stage IC-IV ovarian cancer , an ECOG performance status of @ or lower , and who had never received chemotherapy were randomly allocated in a @:@ ratio to receive either carboplatin ( AUC @ mg/mL per min ) plus paclitaxel ( @ mg/m ( @ ) ) every @ weeks for six cycles or carboplatin ( AUC @ mg/mL per min ) plus paclitaxel ( @ mg/m ( @ ) ) every week for @ weeks .